Is Bicara Therapeutics Inc. Common Stock (BCAX) a Buy, Sell, or Hold?
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$28.1 USD
-$0.05 (-0.18%)
- Volume
- 322.9K
- Average Volume
- 690.69K
- Market Capitalization
- $1.54B
- P/E Ratio
- -10.11
- Dividend Yield
- 0.00%
- Price Target
- $37.00
- Year High
- $30.99
- Year Low
- $9.57
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.85
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Claire Mazumdar Clemon |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BCAX |
| CUSIP | 055477103 |
| CIK | 0002023658 |
| Web | https://www.bicara.com |
| Phone | 617-468-4219 |
| Currency | USD |
| Employees | 103 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 13.85 |
| Quick Ratio | 13.85 |
| Cash Ratio | 8.22 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.92 |
| Price / Cash Flow | -13.20 |
| Price / Book | 3.32 |
Price Target and Rating
| Average Stock Price Forecast | $37.00 |
| High Stock Price Forecast | $42.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -24.05% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.52 |
| Trailing P/E Ratio | -10.11 |
| PEG Ratio | 0.22 |
| P/E Growth | 0.22 |
| Net Income | $-137.95M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -35.89% |
| Return on Assets | -28.42% |
Financials Score
| AltmanZ Score | 22.50 |
| Piotroski Score | 1.00 |
| Working Capital | 505.58M |
| Total Assets | 553.6M |
| Ebit | -157.12M |
| Market Cap | 1.55B |
| Total Liabilities | 39.64M |
Poll Results
About Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) Stock
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited. ...
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 08:30:00
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara's 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on July 1, 2026.
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
2026-06-13 01:01:24
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior to the transaction, with post-transaction direct ownership at 362,152 shares.
2026-05-22 12:50:43
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
2026-05-22 11:10:07
Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer.
2026-05-21 17:00:00
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
2026-05-15 18:42:41
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
2026-05-14 17:10:44
Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.
2026-05-13 15:00:55
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Bicara Therapeutics Inc. Common Stock (BCAX) stock price?
-
Bicara Therapeutics Inc. Common Stock(NASDAQ:BCAX) stock price is $28.1 in the last trading session. During the trading session, BCAX stock reached the peak price of $30.99 while $9.57 was the lowest point it dropped to. The percentage change in BCAX stock occurred in the recent session was --0.18% while the dollar amount for the price change in BCAX stock was -$-0.05.
-
BCAX's industry and sector of operation?
-
The NASDAQ listed BCAX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCAX?
-
Claire Mazumdar Clemon | Chief Executive Officer & Director
Angela Windt | Vice President & Head of Regulatory Affairs
Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance
Gary Bostanxhi | Vice President of Finance & Controller
Rachel Salazar | SVP of R&D Strategy and Operations -
How many employees does BCAX have?
-
Number of BCAX employees currently stands at 103. BCAX operates from 116 Huntington Avenue, Boston, MA 02116, US.
-
Link for BCAX official website?
-
Official Website of BCAX is: https://www.bicara.com
-
How do I contact BCAX?
-
BCAX could be contacted at phone #617-468-4219 and can also be accessed through its website. BCAX operates from 116 Huntington Avenue, Boston, MA 02116, US.
-
How many shares of BCAX are traded daily?
-
The average number of BCAX shares traded daily for last 3 months was 690.69K.
-
What is the market cap of BCAX currently?
-
The market value of BCAX currently stands at $1.54B with its latest stock price at $28.1